Convatec Group PLC (CTEC)
Industry Medical Instruments & Supplies
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
229.40p
Buy
229.80p
0.60p (+0.26%)
Prices updated at 12 Dec 2025, 17:00 GMT
| Prices minimum 15 mins delay
Prices in GBX
ConvaTec Group PLC is a medical products and technologies company focused on therapies for the management of chronic conditions offering wound care, ostomy care, continence and critical care, and infusion devices.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 2,142m | 2,289m | |
| 1,201m | 1,284m | |
| 265m | 332m | |
| 12.38 | 14.49 | |
| 130m | 191m | |
| 456m | 540m | |
| Sales, General and administrative | 825m | 840m |
| Interest expenses | 73m | 74m |
| Provision for income taxes | 37m | 56m |
| Operating expenses | 935m | 952m |
| Income before taxes | 167m | 246m |
| Net income available to common shareholders | 130m | 191m |
| 0.064 | 0.093 | |
| Net interest income | -75m | -78m |
| Advertising and promotion | - | - |
| Net investment income, net | 4m | -18m |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.063 | 0.093 |
| Free cash flow per share | 0.0439 | 0.0998 |
| Book value/share | 0.6241 | 0.6451 |
| Debt equity ratio | 0.7631 | 0.698443 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 870m | 793m |
| Current liabilities | 536m | 512m |
| Total capital | 2,920m | 2,812m |
| Total debt | 1,312m | 1,202m |
| Total equity | 1,693m | 1,689m |
| Total non current liabilities | - | - |
| Loans | 1,227m | 1,123m |
| Total assets | 3,714m | 3,515m |
| Total liabilities | - | - |
| Cash and cash equivalents | 98m | 65m |
| Common stock | 2,046m | 2,044m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 144m | 98m |
| Cash dividends paid | -111m | -130m |
| 238m | 274m | |
| Investments (gains) losses | -286m | -161m |
| 98m | 65m | |
| Net income | - | - |
| 367m | 396m | |
| -129m | -122m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.